Teknova Reports First Quarter 2022 Financial Results

Rhea-AI Summary

In Q1 2022, Teknova reported total revenue of $11.1 million, a 23% increase year-over-year. Excluding Sample Transport revenue, the increase was 37%. The company achieved a cash position of $76.5 million, supporting its growth strategy and expansion efforts, including a new manufacturing facility expected to be operational by year-end. However, the company reported a net loss of $5.5 million and operating expenses that rose to $11.2 million, reflecting increased hiring and public company costs. The 2022 revenue outlook anticipates $45 million to $48 million.

Positive

• Total revenue increased by 23% year-over-year.
• Strong cash position of $76.5 million supports future investments.
• New manufacturing facility expected to enhance production capacity.

Negative

• Net loss increased to $5.5 million, up from $0.7 million year-over-year.
• Operating expenses rose to $11.2 million, significantly impacting profitability.
• Gross margin decreased to 48% from 55.4%.

First quarter 2022 total revenue was $11.1 million, up 23% year-over-year
Excluding Sample Transport revenue, first quarter 2022 total revenue was $11.1 million, up 37% year-over-year
Strong cash position of $76.5 million supports investment in growth strategy

HOLLISTER, Calif., May 11, 2022 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading provider of critical reagents for the discovery, development, and commercialization of drug therapies, novel vaccines, and molecular diagnostics, today announced financial results for the first quarter ended March 31, 2022.

“2022 is off to an excellent start. Order demand remains strong, and we achieved a record revenue quarter,” said Stephen Gunstream, President and CEO of Teknova. “We continue to make progress against our strategic investment priorities, including construction of our new manufacturing facility, which we expect to have online by year end.”

Corporate and Financial Updates

• Achieved record quarterly total revenue of $11.1 million, up 23%, compared to $9.1 million in the first quarter 2021, and up 37% to $11.1 million for the first quarter 2022, compared to $8.2 million for the first quarter 2021, when Sample Transport is excluded
• Remained on track with expansion of our manufacturing capacity in existing facilities and construction of a new, state-of-the-art manufacturing facility
• Reported cash position of $76.5 million, supporting investment in future growth
• Amended existing $27 million credit facility and increased amount available to $57 million to help ensure the Company will have the capital to execute our domestic, organic growth plan

Revenue for the First Quarter 2022

(Dollars in Thousands)	For the Three Months Ended March 31,
		2022				2021
Lab Essentials	$	6,975			$	6,790
Clinical Solutions		3,812				1,071
Sample Transport		6				924
Other		354				293
Total revenue	$	11,147			$	9,078

First Quarter 2022 Financial Results

Total revenue for the first quarter 2022 was $11.1 million, up 23%, compared to $9.1 million in the first quarter 2021, and up 37% to $11.1 million in the first quarter 2022, compared to $8.2 million in the first quarter 2021, when Sample Transport is excluded.

Gross profit for the first quarter 2022 was $5.3 million, compared to $5.0 million in the first quarter 2021. Gross margin for the first quarter 2022 was 48.0% of revenue, compared to 55.4% in the first quarter 2021. The lower gross margin for the first quarter 2022 reflects higher costs associated with expected investments that the Company began making in its current manufacturing capacity and related capabilities to support long-term growth.

Operating expenses for the first quarter 2022 were $11.2 million, compared to $5.9 million in the first quarter 2021. The increase was primarily related to continued hiring across the Company. The increase also reflects costs in the first quarter 2022 associated with operating as a public company when compared to the first quarter 2021.

Net loss for the first quarter 2022 was negative $5.5 million, or negative $0.20 per diluted share, compared to net loss of negative $0.7 million, or negative $0.18 per diluted share, for the first quarter 2021.

Cash used in operating activities for the first quarter 2022 was $5.2 million, compared to cash provided by operating activities of $2.4 million for the first quarter 2021.

Adjusted EBITDA for the first quarter 2022 was negative $4.3 million, compared to break-even for the first quarter 2021. Free Cash Flow was negative $11.1 million for the first quarter 2022, compared to negative $1.5 million for the first quarter 2021.

2022 Revenue Outlook

Teknova now anticipates total revenue of $45 million to $48 million for the fiscal year ending December 31, 2022, which assumes greater than 30% growth at the mid-point of guidance. Total revenue growth is expected to be driven by an approximately 25% increase in Lab Essentials and at least a 60% increase in Clinical Solutions. The Company does not anticipate any material revenue from Sample Transport in 2022.

Conference Call and Webcast

Teknova will host a webcast and conference call on Wednesday, May 11, 2022, beginning at 4:30 p.m. ET. Participants can access the live webcast on the Investor Relations section of the Teknova website and at this link: https://edge.media-server.com/mmc/p/6nk6u95b. The conference call can also be accessed by dialing +1 877-312-1451 for domestic callers and +1 470-495-9521 for international callers. The conference ID number is 7978825. The webcast will be available for replay on the Company’s website approximately two hours after the event.

About Teknova

Teknova is expediting clinical breakthroughs in life sciences by providing custom products and reagents for drug therapies, novel vaccines, and molecular diagnostics. With a focus on agility and customization, Teknova delivers research-grade and GMP products, including cell culture media and supplements, protein and nucleic acid purification buffers, and molecular biology reagents for a multitude of established and emerging applications, including cell and gene therapy, mRNA therapeutics, genomics, and synthetic biology. Teknova's proprietary processes enable the manufacture and delivery of high-quality, custom, made-to-order products with short turnaround times and at scale across all stages of development, including commercialization.

Non-GAAP Financial Measures

This press release contains financial measures that have not been calculated in accordance with U.S. generally accepted accounting principles (GAAP). Teknova uses the following non-GAAP financial measures in assessing the performance of our business and the effectiveness of our business strategies: (a) Adjusted EBITDA and (b) Free Cash Flow.

Teknova defines Adjusted EBITDA as net income (loss) adjusted for interest income (expense), net, provision for (benefit from) income taxes, depreciation expense, amortization of intangible assets, and stock-based compensation expense. Adjusted EBITDA reflects further adjustments to eliminate the impact of certain items, including certain non-cash and other items that we do not consider representative of our ongoing operating performance.

Teknova defines Free Cash Flow as cash provided by (used in) operating activities less purchases of property, plant, and equipment.

Teknova presents Adjusted EBITDA and Free Cash Flow in this press release because Teknova believes that analysts, investors, and other interested parties frequently use these measures to evaluate companies in our industry and that such measures facilitate comparisons on a consistent basis across reporting periods. Teknova also believes such measures are helpful in highlighting trends in our operating results because they exclude items that are not indicative of our core operating performance. Investors should consider non-GAAP financial measures in addition to, and not as a substitute for, or as superior to, measures of financial performance prepared in accordance with GAAP. The non-GAAP financial measures presented by Teknova may be different from the non-GAAP financial measures used by other companies.

A full reconciliation of these non-GAAP measures to the most comparable GAAP measures is included at the end of this release.

Forward-Looking Statements

Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements.” These statements include, but are not limited to, statements relating to our anticipated total revenue, growth in Lab Essentials and growth in Clinical Solutions for 2022, our expectation that our new manufacturing facility will be online by year-end and statements about our prospects and long-term growth strategy. The words, without limitation, “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these or similar identifying words. These forward-looking statements are based on management’s current expectations and beliefs and are subject to uncertainties and factors, all of which are difficult to predict and many of which are beyond our control and could cause actual results to differ materially and adversely from those described in the forward-looking statements. These risks include, but are not limited to, demand for our products; our ability to expand our production capacity and commercial and R&D capabilities; our cash flows and revenue growth rate; our supply chain, sourcing, manufacturing and warehousing; inventory management; risks related to global economic and marketplace uncertainties related to the impact of the COVID-19 pandemic, including the impact of the pandemic on our supply chain; reliance on a limited number of customers for a high percentage of our revenue; potential acquisitions and integration of other companies and other factors discussed in the “Risk Factors” section of our most recent periodic reports filed with the Securities and Exchange Commission (“SEC”), including in our Annual Report on Form 10-K for the year ended December 31, 2021 and subsequent Quarterly Reports on Form 10-Q filed with the SEC, all of which you may obtain for free on the SEC’s website at www.sec.gov. Although we believe that the expectations reflected in our forward-looking statements are reasonable, we do not know whether our expectations will prove correct. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, even if subsequently made available by us on our website or otherwise. We do not undertake any obligation to update, amend or clarify these forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws.

ALPHA TEKNOVA, INC.
Condensed Statements of Operations
(Unaudited)
(In thousands, except share and per share data)

	For the Three Months Ended March 31,
		2022				2021
Revenue	$	11,147			$	9,078
Cost of sales		5,798				4,053
Gross profit		5,349				5,025
Operating expenses:
Research and development		2,013				700
Sales and marketing		1,597				705
General and administrative		7,295				4,161
Amortization of intangible assets		287				287
Total operating expenses		11,192				5,853
Loss from operations		(5,843	)			(828	)
Other (expenses) income, net
Interest (expense) income, net		(13	)			7
Other expense, net		—				1
Total other (expenses) income, net		(13	)			8
Loss before income taxes		(5,856	)			(820	)
Benefit from income taxes		(359	)			(165	)
Net loss	$	(5,497	)		$	(655	)
Net loss per share—basic and diluted	$	(0.20	)		$	(0.18	)
Weighted average shares used in computing net loss per share—basic and diluted		28,030,971				3,599,232

ALPHA TEKNOVA, INC.
Condensed Balance Sheets
(Unaudited)
(In thousands)

	As of March 31,				As of December 31,
		2022				2021
ASSETS
Current assets:
Cash and cash equivalents	$	76,455			$	87,518
Accounts receivable, net		5,978				4,666
Inventories, net		6,426				5,394
Income taxes receivable		1,188				1,188
Prepaid expenses and other current assets		1,891				2,438
Total current assets		91,938				101,204
Property, plant and equipment, net		37,059				29,810
Operating right-of-use lease assets		19,661				—
Goodwill		16,613				16,613
Intangible assets, net		18,417				18,704
Other non-current assets		396				180
Total assets	$	184,084			$	166,511
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable	$	3,028			$	2,248
Accrued liabilities		7,510				5,495
Current portion of operating lease liabilities		2,098				—
Total current liabilities		12,636				7,743
Deferred tax liabilities		2,793				3,153
Other accrued liabilities		253				273
Long-term debt, net		11,916				11,870
Deferred rent		—				269
Long-term operating lease liabilities		17,938				—
Total liabilities		45,536				23,308
Stockholders’ equity:
Preferred stock		—				—
Common stock		—				—
Additional paid-in capital		151,583				150,741
Accumulated deficit		(13,035	)			(7,538	)
Total stockholders’ equity		138,548				143,203
Total liabilities and stockholders’ equity	$	184,084			$	166,511

ALPHA TEKNOVA, INC.
Condensed Statements of Cash Flows
(Unaudited)
(In thousands)

	For the Three Months Ended March 31,
		2022				2021
Operating activities:
Net loss	$	(5,497	)		$	(655	)
Adjustments to reconcile net loss to net cash (used in) provided by operating activities:
Bad debt expense		7				(88	)
Inventory reserve		(4	)			(2	)
Depreciation and amortization		751				652
Stock-based compensation		787				183
Deferred taxes		(360	)			(164	)
Amortization of debt financing costs		46				—
Non-cash lease expense		106				—
Other		—				(10	)
Changes in operating assets and liabilities:
Accounts receivable		(1,319	)			400
Inventories		(1,028	)			(295	)
Income taxes receivable		—				(177	)
Prepaid expenses and other current assets		547				348
Accounts payable		237				1,283
Accrued liabilities		762				847
Other		(236	)			79
Cash (used in) provided by operating activities		(5,201	)			2,401
Investing activities:
Purchase of property, plant and equipment		(5,917	)			(3,884	)
Proceeds from loan to related party		—				529
Proceeds on sales of short-term marketable securities		—				1,132
Proceeds from maturities of short-term marketable securities		—				695
Cash used in investing activities		(5,917	)			(1,528	)
Financing activities:
Proceeds from long-term debt		—				11,889
Debt issuance costs		—				(153	)
Payment of costs related to initial public offering		—				(1,458	)
Proceeds from exercise of stock options		55				—
Cash provided by financing activities		55				10,278
Change in cash and cash equivalents		(11,063	)			11,151
Cash and cash equivalents at beginning of period		87,518				3,315
Cash and cash equivalents at end of period	$	76,455			$	14,466

ALPHA TEKNOVA, INC.
Reconciliation of Non-GAAP Measures to the Most Comparable GAAP Measures
(Unaudited)
(In thousands)

	For the Three Months Ended March 31,
		2022				2021
Net loss – as reported	$	(5,497	)		$	(655	)
Add back:
Interest (expense) income, net		(13	)			7
Benefit from income taxes		(359	)			(165	)
Depreciation expense		464				365
Amortization of intangible assets		287				287
EBITDA	$	(5,092	)		$	(175	)
Other and one-time expenses:
Stock-based compensation expense		787				183
Adjusted EBITDA	$	(4,305	)		$	8
	For the Three Months Ended March 31,
		2022				2021
Cash (used in) provided by operating activities	$	(5,201	)		$	2,401
Purchase of property, plant and equipment		(5,917	)			(3,884	)
Free Cash Flow	$	(11,118	)		$	(1,483	)

 

FAQ

What were Teknova's total revenues for Q1 2022?

Teknova's total revenues for Q1 2022 were $11.1 million, a 23% increase compared to Q1 2021.

What is Teknova's revenue outlook for 2022?

Teknova anticipates total revenue between $45 million to $48 million for the fiscal year ending December 31, 2022.

What was Teknova's net loss in Q1 2022?

Teknova reported a net loss of $5.5 million in Q1 2022.

How much cash does Teknova have on hand?

Teknova reported a strong cash position of $76.5 million.

What are the key drivers for Teknova's revenue growth in 2022?

Revenue growth is expected to be driven by a 25% increase in Lab Essentials and at least a 60% increase in Clinical Solutions.